SCHEMBL3313074

SCHEMBL3313074

NC1(C=O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL881429 0.86
SCHEMBL3318734 0.86
SCHEMBL25294321 0.83 TSHR (0.36)
SCHEMBL1780853 0.83
SCHEMBL13939240 0.79 GAA (0.31)
SCHEMBL18232561 0.78
SCHEMBL12380783 0.75
SCHEMBL18232563 0.74
Nitrous Acid SCHEMBL597561 0.73 TSHR (0.34)
SCHEMBL23586974 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-02-13 US claimed
CN-116730972-A Crown ether supermolecular compound with phase change characteristic and preparation method thereof 东南大学 2023-09-12 CN claimed
WO-2021159993-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF PHARMABLOCK SCIENCES (NANJING) , INC. (CN) 2021-08-19 WO claimed
WO-2021113479-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-06-10 WO claimed
US-20210171535-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-06-10 US claimed
CN-110085879-A A kind of Co9S8/ sulphur nitrogen is co-doped with carbon composite and preparation method thereof 中国科学院山西煤炭化学研究所 2019-08-02 CN claimed
CN-105837584-B The imidazole radicals imidazoles of condensation as antiviral compound 吉利德制药有限责任公司 2018-07-13 CN claimed
CN-106432254-A Antiviral compounds inhibitors of HVC NS5B 吉利德制药有限责任公司 2017-02-22 CN claimed
CN-105837584-A Condensed imidazolylimidazoles as antiviral compounds 吉利德制药有限责任公司 2016-08-10 CN claimed
CN-103328480-A Condensed imidazolylimidazoles as antiviral compounds GILEAD SCIENCES INC 2013-09-25 CN claimed
US-20030050246-A1 Peptides having antiangiogenic activity ABBOTT LABORATORIES 2003-03-13 US claimed
US-20030045477-A1 Peptides having antiangiogenic activity ABBOTT LABORATORIES 2003-03-06 US claimed
WO-2003011896-A1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2003-02-13 WO claimed
CN-1347412-A aryloxy dithiazole dioxides BAYER AG (DE) 2002-05-01 CN claimed
CN-1220663-A Substituted phenyl uracils BAYER AG (DE) 1999-06-23 CN claimed
US-5719280-A REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID SYNTEX (U.S.A.) INC. (US) 1998-02-17 US claimed
CN-1151735-A Benzocycloalkylazolethione derivatives SYNTEX INC (US) 1997-06-11 CN claimed
EP-0757677-A1 BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES SYNTEX (U.S.A.) INC. (US) 1997-02-12 EP claimed
US-5538988-A CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS SYNTEX (U.S.A.) INC. 1996-07-23 US claimed
WO-1995029165-A2 BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-11-02 WO claimed